Funding for this research was provided by:
Hanmi Pharmaceutical Co., Ltd.
Text and Data Mining valid from 2019-04-03
Received: 18 December 2018
Accepted: 27 March 2019
First Online: 3 April 2019
Compliance with ethical standards
: Yung-Jue Bang has served in consultant/advisory board roles for AstraZeneca, Novartis, Genentech/Roche, MSD, Bayer, BMS, Eli Lilly, Merck Serono, Taiho, Daiichi-Sankyo, Astellas, BeiGene, Green Cross, Samyang Biopharmaceuticals and Hanmi, and has received research grants from AstraZeneca, Novartis, Genentech/Roche, MSD, Merck Serono, Bayer, GSK, BMS, Pfizer, Eli Lilly, Boeringer-Ingelheim, MacroGenics, Boston Biomedical, FivePrime, CKD Pharma, Ono, Taiho, Takeda, BeiGene, Green Cross, Curis, Daiichi Sankyo and Astellas. Soo-A Jung and NaMi Lee are employees of Hanmi Pharmaceutical Co., Ltd., Seoul, South Korea. The other authors declare no conflicts of interest.
: All procedures followed were in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guidelines and the study was approved by the Institutional Review Board of each participating center. All patients provided written informed consent before enrollment.